Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Adcentrx Therapeutics

Request full access

Adcentrx Therapeutics Inc.

San Diego, United StatesFounded 2021Biotech & Life Sciences

About Adcentrx Therapeutics

Adcentrx Therapeutics, a clinical-stage biotechnology firm founded in 2021, is focused on the development of protein conjugate therapeutics for oncology and other severe diseases. The company was established by Dr. Hui Li, who currently serves as President and CEO, bringing over two decades of experience in drug discovery and business development within the biotech and pharmaceutical sectors. Before Adcentrx, Dr. Li was the CEO of Levena Biopharma, an antibody-drug conjugate (ADC) subsidiary of Sorrento Therapeutics, and held senior roles at PPD and Pfizer Global Research & Development. This extensive background in ADC development directly informs the company's strategic direction.

Adcentrx operates in the highly specialized market of antibody-drug conjugates, which are therapies that combine the precise targeting capabilities of antibodies with the potent cell-killing power of small molecule payloads. The company's business model is centered on advancing its proprietary pipeline of ADC candidates through clinical trials. Revenue generation is anticipated from the successful commercialization of these therapies, either independently or through strategic partnerships and licensing agreements with larger pharmaceutical companies. The company has secured significant funding to advance its pipeline, raising a total of $101 million over three Series A rounds, with investors including Eight Roads Ventures, CBC Group, F-Prime Capital, and Quan Capital.

The company's core offering is its proprietary ADC technology toolbox, which includes the i-Conjugation™ platform, designed to overcome challenges faced by previous generations of ADCs. This technology enables the creation of ADCs with a stable drug-to-antibody ratio, aiming for improved safety and efficacy. Adcentrx's lead product candidate, ADRX-0706, is a Nectin-4 targeting ADC that entered a first-in-human Phase 1a/b clinical trial in the latter half of 2023 for the treatment of advanced solid tumors. Another promising candidate, ADRX-0405, is a potential first-in-class ADC targeting STEAP1 for advanced solid tumors, which received FDA clearance for its Investigational New Drug (IND) application. The company is developing other candidates with the goal of advancing at least one new therapy into the clinic each year.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2021
Headquarters
San Diego, United States
Employees
27
Open positions
None listed
Dealroom signal
27.6/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Dec 2023 $13M $250M Partners Investment · Quan Capital · Eight Roads Ventures ↗
SERIES AOther financing Apr 2023 $38M $250M ABio-X · F-Prime · Delta Capital · Lighthouse Capital ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Adcentrx Therapeutics website traffic

Latest recorded traffic for Adcentrx Therapeutics is 3.1K monthly website visits, up 0% over the last three months. Adcentrx Therapeutics's team declined 10% over the past year.

Latest monthly visits3.1K 3-month web change0% 1-year team growth-10%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Adcentrx Therapeutics in the San Diego ecosystem

Live from Dealroom

The Adcentrx Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A11 investors entered at this stage

  • CBC Group
  • Boyu Capital
  • Zoo Capital
  • Eight Roads Ventures
  • ABio-X
  • F-Prime
  • Delta Capital
  • Lighthouse Capital
  • Trinity Innovation Fund
  • Partners Investment
  • Quan Capital
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States88%
🇨🇳 China12%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Adcentrx Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Adcentrx Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.